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 2 
Summary  1 
Certain limitations of evidence available on drugs and devices at the time of market 2 
approval often persist in the post-marketing period. Too often, post-marketing research 3 
landscape is fragmented. When regulatory agencies require pharmaceutical and device 4 
manufacturers to conduct studies in the post-marketing period, these studies may remain 5 
incomplete many years after approval. Even when completed, many post-marketing studies lack 6 
meaningful active comparators, have observational designs, and may not collect patient-relevant 7 
outcomes. It is crucial for regulators, in collaboration with the industry and patients, to ensure 8 
that the important questions that are unanswered at the time of drug and device approval are 9 
resolved in a timely fashion during the post-marketing phase. We propose a set of seven key 10 
guiding principles that we believe will provide the necessary incentives for pharmaceutical and 11 
device manufacturers to generate comparative data in the post-marketing period. First, regulators 12 
and pharmaceutical companies (for drugs), notified bodies and manufacturers (for devices) 13 
should develop customised evidence generation plans, ensuring that future post-approval studies 14 
address any limitations of the data available at the time of market entry that would influence the 15 
benefit-risk profiles of drugs and devices. Second, post-marketing studies should be designed 16 
hierarchically: priority should be given to efforts aimed at evaluating a product’s net clinical 17 
benefit in randomised trials compared with current known effective therapy, whenever possible, 18 
to address common decisional dilemmas. Third, post-marketing studies should incorporate 19 
active comparators as appropriate. Fourth, use of non-randomised studies for the evaluation of 20 
clinical benefit in the post-marketing period should be limited to instances when the magnitude 21 
of effect is deemed to be very large or when it is possible to reasonably infer the comparative 22 
benefits or risks in settings where doing a randomised trial is not feasible. Fifth, efficiency of 23 
randomised trials should be improved by streamlining patient recruitment and data collection 24 
through innovative design elements. Sixth, governments should directly support and facilitate the 25 
production of comparative post-marketing data by investing in the development of collaborative 26 
research networks and data systems that reduce the complexity, cost, and waste of rigorous post-27 
marketing research efforts. Seventh, financial incentives and penalties should be developed or 28 
more actively reinforced. 29 
 30 
  31 
 3 
                      The turn of 21st century marked a period when a number of high-profile safety concerns 32 
for commonly-used treatments brought significant attention to the role of regulatory agencies in 33 
protecting public health.1,2 For example, rofecoxib, a nonsteroidal anti-inflammatory drug that 34 
was approved by the FDA in 1999, was withdrawn from the market in 2004 after a series of 35 
studies found that it increased the risk of major cardiovascular events.3,4 The rise and fall of 36 
rofecoxib brought into sharp focus the limitations of the post-marketing research landscape that 37 
had until then relied on ad-hoc efforts to generate data on newly-approved drugs and devices.5  38 
 Acknowledging the need to monitor and evaluate drugs not only prior to their approval 39 
but throughout their life span, regulators in Europe and the US have since adopted a “lifecycle” 40 
approach. There has been significant progress on the post-marketing safety evaluation of drugs 41 
both in Europe and the US, as represented by the Sentinel initiative in the US,6 and the 42 
European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) in 43 
the European Union7  (see Online Appendix). Although similar efforts are currently underway 44 
for devices, such as the National Evaluation System for health Technology in the US, NEST, 45 
these are still in their infancy.8 Post-marketing safety surveillance of medical devices remains 46 
decentralised in Europe.9 47 
 Together with safety, post-market evaluation of clinical benefit for drugs and devices is 48 
important for two reasons (Figure 1). First, an increasing proportion of approvals have recently 49 
benefited from regulatory programs aimed at expediting the development and review of new 50 
drugs.10 Regulators created expedited programs to address unmet patient need in certain serious 51 
and debilitating conditions. Approvals in such programs typically rely on earlier-stage data than 52 
what is traditionally required for market entry.11 Second, regulatory agencies have recently 53 
articulated their vision for a future where the line separating pre-approval and post-approval 54 
periods is blurred. Instead of making binary decisions as to whether a new treatment should be 55 
approved or rejected on the basis of available data, regulators are adopting so-called “adaptive” 56 
approaches to iterative data collection and evaluation throughout the life-span of therapies.12 57 
Historically, evidence standards for medical device approvals have been substantially lower than 58 
those for drugs (even more so in Europe); post-approval evaluation is therefore essential.13  59 
 There are significant challenges associated with relying on post-marketing research to 60 
address the limitations of data generated on clinical benefit prior to approval.14 The relatively 61 
little investment on post-approval data needs has led to a fragmented research environment.15 62 
Consequently, the key limitations of the data available on the clinical benefit of drugs and 63 
devices at the time of market approval have largely persisted in the post-marketing period.  64 
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 In this second article of the Series, we focus on the potential for generation of 65 
comparative effectiveness evidence in the post-marketing period and its coordination with pre-66 
approval research efforts. Our focus is on drugs and devices (implantable and high-risk devices), 67 
however the issues and principles covered in this article apply more broadly to other 68 
interventions, such as surgery or even health policy interventions. We first review some of the 69 
current key challenges of post-marketing research and its three important methodological 70 
features: study designs, endpoints and types of comparators. We then propose strategies to 71 
improve the future availability of comparative data on new drugs and devices after market entry. 72 
 73 
Current post-marketing research landscape 74 
Once drugs are approved by regulatory agencies, research activity on their clinical 75 
benefits is primarily influenced by regulatory and market forces.16 Regulatory agencies in both 76 
Europe and the US frequently recommend the completion of post-marketing studies to address 77 
the uncertainties that remain at the time of drug approval. For drugs approved through some 78 
expedited programs (accelerated approval in the US and conditional marketing authorisation in 79 
Europe), regulators may also have post-marketing study requirements. In fact, continued market 80 
availability of certain expedited drugs may be conditional on the timely completion of such 81 
mandatory post-marketing studies. Although the FDA can require post-approval studies for 82 
high-risk devices, the lack of a centralised regulatory agency for medical devices in Europe 83 
means that post-approval evaluation of benefit remains ad-hoc under the discretion of notified 84 
bodies.17 In terms of market forces, following marketing authorisation, pharmaceutical 85 
manufacturers have a limited period of time (usually 10-12 years) during which they have market 86 
protections on their approved products. During this period, companies naturally have incentives 87 
to invest in research to broaden the approved indications of their products.  88 
 89 
Regulatory agency-driven research in the post-marketing period 90 
According to a recent evaluation of FDA approvals from 2009 to 2012, the vast majority 91 
of post-marketing commitments, which are not required by any statute or regulation, were for 92 
non-clinical studies.18 Often, post-marketing studies required by regulatory agencies are 93 
insufficiently described and do not contain enough information to characterise important study 94 
design features such as comparators, randomisation, and endpoints.19 This is partly because post-95 
marketing studies are rarely underway (or even designed) at the time of market entry. In a recent 96 
systematic review, median times permitted by FDA for pharmaceutical companies to submit 97 
protocols for their required post-marketing studies ranged from 3 to 15 months after approval.20  98 
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 Post-marketing commitments and requirements may remain incomplete many years after 99 
approval.14 Pharmaceutical companies seldom meet regulatory deadlines in the post-marketing 100 
period: only half the studies started in 2009 and 2010 had been completed by the end of 2015, 101 
and some companies failed to submit required annual status reports, with the FDA rarely 102 
imposing penalties for lack of due diligence.21 For drugs that received FDA’s accelerated 103 
approval from 2009 to 2013, almost half of incomplete studies were either terminated or delayed 104 
by more than one year.22 Of the 93 new cancer indications that received FDA’s accelerated 105 
approval between 1992 and 2017, 51 (55%) fulfilled their post-marketing requirements and 106 
verified clinical benefit, 37 (40%) indications did not complete confirmatory trials or verified 107 
benefit, and 5 indications (5%) were withdrawn from the market, as they did not show clinical 108 
benefit when confirmatory post-approval trials were completed.23 Perhaps even more critical 109 
than the timeliness of these trials is that they generate sufficient reliable evidence on proven 110 
effectiveness of therapies to guide future practice long term. For instance, the recently reported 111 
results of ANNOUNCE, a large RCT of olaratumab in patients with advanced or metastatic 112 
soft-tissue sarcoma, did not confirm an apparent survival benefit of olaratumab in combination 113 
with doxorubicin as compared to doxorubicin alone, a standard-of-care treatment and its FDA 114 
approval has now been withdrawn.24  115 
 In Europe, EMA implemented 69 obligations for 26 conditionally-authorised medicines 116 
between 2006 and 2016. Over a third of these obligations were subsequently changed and more 117 
than half had delays in data submission.25 Two of the 26 drugs were ultimately withdrawn from 118 
the market for commercial reasons, ten were switched to regular approval, and 14 were still 119 
under conditional approval, oftentimes several years after market entry.26,27  120 
 Even when required confirmatory studies are completed, they resemble the design 121 
features of pre-marketing studies. Studies about drugs targeting rare conditions have similar 122 
designs as those investigating drugs treating non-rare conditions in the post-marketing period.28 123 
Among novel therapeutic agents that received accelerated approval between 2000 and 2013, 124 
clinical benefit was often confirmed in post-marketing trials which had similar design elements to 125 
preapproval trials, including reliance on non-randomised designs, and surrogate endpoints.22 126 
Cancer drugs approved by the FDA based on the surrogate endpoint of response rate were often 127 
tested in post-marketing studies that captured other similar surrogate endpoints.29  128 
Among high-risk therapeutic devices approved via FDA’s most stringent pathway for 129 
medical devices, implementation of post-approval studies has been challenging.30 According to 130 
one review, only approximately 13% of initiated post-marketing studies were completed between 131 
three and five years after FDA approval.31 No corresponding figures are available from Europe; 132 
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historically, any relevant post-marketing requirements by notified bodies have not been publicly 133 
disclosed. The revised Medical Device Regulations, which will come into effect in May 2020 will 134 
require public disclosure of such information in the European Union Database for Medical 135 
Devices (EUDAMED).32 136 
  137 
Industry-initiated research in the post-marketing period 138 
Most new drugs have industry-initiated post-marketing studies; however, the majority of 139 
these are conducted in therapeutic areas outside of the approved indication (or including 140 
participants that extend beyond the indicated population).28 Such studies could be useful if they 141 
produce unbiased evidence on clinically relevant outcomes for the original approved indication 142 
and beyond. Instead, companies conduct post-marketing studies to seek approvals in new 143 
indications or expand their already-approved indications.33,34 In addition, most post-approval 144 
studies are small and many are not designed to directly evaluate the clinical benefits of newly-145 
approved drugs.35 In a large systematic evaluation, the quantity and quality of post-approval 146 
clinical evidence varied substantially for novel drugs first approved by the FDA on the basis of 147 
limited evidence, with few controlled studies published after approval that confirmed clinical 148 
benefit using clinical outcomes for the original FDA approved indication.36 Post-approval 149 
evaluation of high-risk devices is sparse.31 150 
 Evidence to date suggests that valid data confirming the clinical benefits of drugs and 151 
devices on the basis of patient-centred and clinically-relevant outcomes may not routinely 152 
emerge in the post-marketing period.37 According to a recent study, only one-fifth of required 153 
post-marketing studies of cancer drug indications approved via the FDA’s accelerated approval 154 
pathway over the past quarter century demonstrated improvements in overall survival in 155 
randomised controlled trials, though patients may occasionally derive quality of life benefits in 156 
some limited cases without a survival gain.38  157 
 158 
Coordination of evidence generation between before and after approval 159 
The nature of the current post-marketing research contributes to the well-known 160 
problem of research waste.39 To produce medical knowledge that is clinically informative and 161 
satisfies the goals of different stakeholders, increased coordination over the life-course of a 162 
product is required. It is, therefore, crucial for regulators, in collaboration with patient groups, 163 
health technology assessment organisations, payers, pharmaceutical and device manufacturers, 164 
and public funders, to ensure that the important questions that are unanswered at the time of 165 
approval are resolved in a timely fashion during the post-marketing phase.  166 
 7 
 While some regulatory flexibility in approval standards is important in therapeutic areas 167 
with significant unmet need, such cases warrant a careful examination of the gap between the 168 
existing (what is available) and the optimal (what is needed) evidence that is required for decision 169 
making in clinical practice and health policy. If planned carefully, post-marketing studies on 170 
drugs and devices can generate timely evidence across the lifecycle of a medical product to 171 
reduce the substantial residual uncertainties at the time of regulatory approval.  172 
 173 
What is the “optimal” quantity and quality of evidence to inform decision-making in the post-marketing period? 174 
Although it may be difficult to develop universal evidence standards for all therapeutic 175 
areas, there are a number of important principles that determine the internal validity and 176 
generalisability of research findings.40 These principles are summarised by the PICOTS 177 
(populations, interventions, comparators, outcomes, time periods, and study designs) 178 
framework.41 Clinical studies supporting the regulatory approval of new drugs and high-risk 179 
devices often include highly-selective and narrowly-defined patient populations (P); adopt a strict 180 
definition of the intervention implemented in protocol-driven settings (I); examine the clinical 181 
benefit of the new product against a placebo or no treatment (C); evaluate surrogate measures of 182 
effect rather than clinical outcomes (O); have short follow-up durations (T); and lack important 183 
study design elements that are required to establish internal validity, i.e., attribute observed 184 
effects to the treatment rather than other factors (S).  185 
An important dimension of comparative effectiveness research in the post-marketing 186 
period should be to extend the evidence base to patients for whom the current evidence is 187 
considered not applicable over a longer period of time and across a broader definition of the 188 
intervention. For example, the mean age of patients included in most trials of antiplatelet drugs 189 
in secondary prevention of stroke was about 60 years compared to over 75 years in a population-190 
based study.42 Although the risk of bleeding complications at age <65 years in the population-191 
based cohort was reassuringly similar to that in the previous trials, both the risk and severity of 192 
bleeding complications in patients aged over 75 years was several-fold greater and outcomes 193 
were substantially worse.42 194 
While it is desirable that post-marketing research efforts address the limitations of the 195 
evidence base across the full spectrum of the PICOTS framework, priority should be given to 196 
research efforts that are aimed at confirming clinical benefits (new and long-term outcomes) of a 197 
new product before setting out to examine its generalisability (expanded patients groups) 198 
(Figure 2). Our primary focus in this article is on the three key methodological features of post-199 
marketing studies – choice of comparators (C), study outcomes (O), and study designs (S). If 200 
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data limitations persist on these three features after approval, it remains difficult to establish 201 
whether a new drug or device works, and whether it works any better or worse than existing 202 
alternatives.   203 
 204 
Choice of comparators  205 
Less than a third of studies in the published clinical literature adopt active comparators43 206 
and only 22% of studies registered in clinicaltrials.gov have active comparators with the 207 
remainder employing either placebo or no control.44 Clinical trials with active comparators are 208 
more likely to be sponsored by non-commercial funders, including governments.43,44 Some of the 209 
largest, and most influential, comparative effectiveness trials in the post-marketing period have 210 
been publicly funded. For example, one of the landmark comparative effectiveness trials in 211 
psychiatry, the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study, which 212 
was funded by the US National Institutes Health, compared in a head-to-head fashion the 213 
relative effectiveness of second-generation antipsychotic drugs with perphenazine, an older 214 
agent, for the treatment of patients with chronic schizophrenia and found that they were not 215 
significantly different in overall effectiveness.45 Another publicly-funded comparative 216 
effectiveness trial, the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack 217 
Trial (ALLHAT), showed that inexpensive thiazide-type diuretics were more effective than some 218 
of the newer treatment classes.46  219 
Comparative effectiveness studies need not always be undertaken as head-to-head 220 
comparisons, especially when the addition of therapies to standard care is being considered. A 221 
factorial (or partial factorial design) may be preferred in some instances. For instance, the Second 222 
International Study of Infarct Survival (ISIS-2) trial showed that the addition of aspirin or 223 
streptokinase provided added benefit over not giving either treatment.47  224 
 Most comparative effectiveness research sponsored by manufacturers focus on their own 225 
products. Previous examinations of the geometry of treatment networks in different therapeutic 226 
areas have revealed key insights about the preferences of industry sponsors regarding 227 
comparators when designing their research studies.48 Industry-sponsored studies are not 228 
necessarily of lower methodological rigour;49,50 however, many such studies are designed in a way 229 
to produce conclusions in favour of the sponsored intervention by selecting comparators with an 230 
inferior benefit or harm profile.51 The vast literature on antidepressants for depression illustrates 231 
this phenomenon.52 Therefore, the choice of comparators is one of the primary mechanisms 232 
through which trial sponsors shape the cumulative evidence available to guide treatment 233 
decisions in the post-marketing period.53 Such practices have long-lasting implications on the 234 
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relevance of the evidence base for decision-making and highlight the need for regulatory input 235 
on the design of post-marketing studies and the conduct of more such studies that are entirely 236 
independent of industry sponsors.  237 
For some truly innovative treatments, active comparator may not exist. In other cases, 238 
identification of active comparators may be difficult. What is essential is that the new therapy is 239 
compared with the current best standard of care (which may be in addition to or as an alternative 240 
to such standard of care). Since most therapies that benefit from expedited regulatory programs 241 
are for conditions with an unmet need and sometimes without a recognised established therapy, 242 
the choice of comparator in the post-marketing period may include the best supportive care 243 
(such as for patients with advanced cancer having failed all lines of effective therapy). Physician’s 244 
choice as comparator may also be considered in areas when choosing the appropriate 245 
comparator proves difficult.54 246 
   247 
Choice of study outcomes 248 
Study outcomes can be broadly divided into two categories: clinical outcomes and surrogate 249 
measures. Clinical outcomes (such as mortality, morbidity, or health-related quality of life) 250 
represent direct clinical benefits that are meaningful to patients and clinicians. Surrogate 251 
measures (such as laboratory tests, radiographic images, or other biomarkers that correlate with 252 
clinical outcomes), on the other hand, are substitutes for clinical outcomes and typically do not 253 
represent direct clinical benefit. An observed correlation between intermediate measures and 254 
clinical outcomes – however strong – is not adequate to establish surrogacy; changes in a 255 
surrogate measure should also reliably predict changes in the clinical outcome, both at the 256 
individual and aggregate levels.55 Usually, it is easier to demonstrate the surrogacy of measure at 257 
the aggregate level. For instance, low-density lipoprotein (LDL) cholesterol is associated with 258 
coronary heart disease, and, on average, lowering LDL-cholesterol reduces the risk of coronary 259 
heart disease.56 However, specific individuals who suffer coronary events may not always be 260 
those with the worst LDL-cholesterol response.   261 
Non-validated surrogate measures may fail to predict treatment effects on clinical 262 
outcomes. For instance, despite the (inverse) association between high-density lipoprotein 263 
(HDL) cholesterol and coronary heart disease, RCTs of investigational therapeutic agents have 264 
failed to demonstrate a reduction in coronary heart disease risk by increasing HDL cholesterol 265 
levels.57,58 Anti-diabetic agents that effectively lower baseline HbA1c levels do not lower the risk 266 
of all-cause mortality or deaths due to cardiovascular causes.59 In the Cardiac Arrythmia 267 
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Suppression Trial, use of encainide and flecainide was associated with excess mortality compared 268 
with placebo, despite their effect on a surrogate measure, suppression of ventricular ectopy.60 269 
Regulatory agencies in both Europe and the US have a long history of approving new 270 
treatments on the basis of their effects on surrogate measures alone. Between 2005 and 2012, 271 
approximately half of pivotal clinical studies that supported the FDA approval of new drugs 272 
used surrogate measures as primary endpoints.61 Most high-risk device approvals in the US are 273 
supported by surrogate measures alone. Surrogate measures have feasibility advantages over 274 
clinical outcomes in drug and device development. Surrogate measures typically require smaller 275 
sample sizes and shorter study durations to achieve a statistically significant improvement, 276 
thereby substantially reducing the cost and complexity of studies, thus possibly allowing faster 277 
patient access to new treatments. According to a recent evaluation, using progression-free 278 
survival and response rate  in cancer trials was associated with an average 11-month and 19-279 
month, respectively, shorter clinical development period compared with using overall survival.62  280 
Although certain surrogate measures are well-validated, many of the surrogate measures 281 
used for approval decisions are not comprehensively validated, highlighting the need to confirm 282 
clinical benefit in the post-marketing period. Surrogate measures are particularly common in 283 
cancer trials. More than four fifths of pivotal studies that supported the approval of cancer drugs 284 
in the US relied on surrogate measures alone.61 According to systematic reviews, the relationship 285 
between surrogate measures (such as tumour response or progression-free survival) and clinical 286 
outcomes (such as overall survival or quality-of-life) is often poor.63–66  287 
Surrogate measures used for approval decisions have important implications for clinical 288 
practice and health policy. In some cases, improvements observed on surrogate measures may be 289 
false positives. According to a large meta-epidemiological review, clinical studies using surrogate 290 
measures produced substantially exaggerated results compared with those using clinical 291 
outcomes (with relative odds ratios ranging between 1.28 and 1.48).67 In addition, clinical studies 292 
using surrogate measures were twice as likely to find “positive” results compared with studies 293 
that captured clinical outcomes.67  294 
For example, bevacizumab was approved for the treatment of metastatic breast cancer 295 
on the basis of its effect on progression-free survival. In a subsequent trial, however, there was 296 
no evidence that bevacizumab improved overall survival among women with this condition.68 In 297 
some cases, drugs approved on the basis of surrogate measures alone may turn out to be 298 
harmful. In the recent BELLINI trial, patients with relapsed, refractory multiple myeloma who 299 
received venetoclax had worse overall survival than those who received the control treatment 300 
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even though venetoclax appeared superior in terms of its effect on surrogate measures of 301 
progression-free survival and response rate.69  302 
 303 
Choice of study designs 304 
The best way to establish the clinical effectiveness of a new treatments to perform a 305 
RCT.70 In non-randomised studies, treatment assignment is influenced by the patient, the 306 
provider, or even the setting, resulting in differences in distribution of prognostic factors in 307 
patient groups receiving different treatments. Such confounding by indication (or treatment 308 
selection bias) is a material threat to the internal validity of non-randomised studies and explains 309 
why clinicians, researchers, and policymakers are often reluctant to use observational studies to 310 
reach conclusions about the comparative effectiveness of treatments.71  311 
 Despite the intractable problems of confounding, there is growing enthusiasm for 312 
expanding the use of non-randomised studies in the regulatory setting, driven in part by the 313 
increased availability of routinely collected data, such as electronic health records, and methods 314 
to process and analyse these data.72,73 The US 21st Century Cures Act, passed in 2016, allows the 315 
use of non-randomised studies when approving new indications for already-approved drugs.74 316 
While non-randomised studies are helpful in monitoring the safety profiles of treatments, they 317 
have well-known validity limitations when determining the clinical effect of treatments (of either 318 
benefit or harm) with small-to-moderate effect sizes.75  319 
 Many methods exist that try to control for confounding in non-randomised studies. 320 
Some of them (such as propensity score adjustment and instrumental variables) have become 321 
more popular over time,43 but it cannot be secured that such approaches control confounding 322 
effectively.76 When instrumental variables were used, non-randomised studies failed to control 323 
for one or more potentially major confounders, which could lead to over-estimation, under-324 
estimation or complete reversal of the effect estimate.77 While researchers and regulatory 325 
agencies continue to develop approaches to address confounding and bias in non-randomised 326 
studies, it will still be important to understand fitness of use and ensure validity for a given 327 
context.    328 
 329 
Generating comparative effectiveness in the post-marketing period 330 
We recommend seven strategies which may promote and facilitate the generation of 331 
post-marketing comparative effectiveness research aimed at addressing the limitations of the 332 
evidence available on new drugs and devices at the time of approval (Table 1).  333 
 334 
 12 
1. Ensure post-marketing studies address clinically important evidence gaps  335 
In 2012, the Institute of Medicine in the US recommended implementing a Benefit and 336 
Risk Assessment and Management Plan to capture in a single “living” document the FDA’s 337 
evaluation of the known benefits and risks during the entire life cycle of the product.78,79 This 338 
recommendation has not been adopted, highlighting the challenges associated with establishing 339 
and continuously monitoring the fast-evolving evidence base on approved products. Without 340 
such a document or living library, however, it is not possible for regulators, health technology 341 
assessment organisations, payers, clinicians, and patients to stay abreast of the evolving research 342 
on new products. When a new product enters the market, it remains difficult for stakeholders in 343 
the health system to characterise and quantify the remaining uncertainties on its benefits, 344 
especially in relation to the optimal amount of evidence needed to inform decisions. Regulatory 345 
agencies are uniquely positioned to summarise what is and is not known about the comparative 346 
benefits and harms of new products when they enter the market. One exception is the notified 347 
bodies in Europe, as they do not conduct the evaluation of evidence submitted by device 348 
manufacturers.  349 
With input from patient groups, health technology assessment organisations in Europe 350 
and the federal and state-level payers in the US, FDA and EMA should develop a customised 351 
plan to guide subsequent post-marketing research efforts and ensure that future studies 352 
correspond directly to the limitations of the data available at the time of market entry. In 353 
Europe, the recently published guidance on the Summary of Safety and Clinical Performance for 354 
high-risk and implantable medical devices will require manufacturers to summarise “if there are 355 
any unanswered questions relating to the use of the device.”80 Although health technology 356 
assessment organisations and payers differ in their evidence requirements, post-marketing 357 
research plans could focus on a minimum set of core principles that are shared among different 358 
stakeholders,81 namely the choice of comparators, study outcomes, and study designs.  359 
 360 
2. Design post-marketing studies hierarchically 361 
In recent years, an increasing proportion of new products have entered the market on 362 
the basis of non-randomised studies that lack active comparators and include only surrogate 363 
measures.82 When data on drugs and devices deviate from the optimal quantity and quality of 364 
evidence, manufacturers should be required by regulators to confirm their clinical benefit in a 365 
timely manner.14 The industry’s drug and device development plans should include a detailed, 366 
feasible, and timely research plan for generating this evidence. Even though post-marketing 367 
studies aimed at extending the approved indication could generate useful evidence on the 368 
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effectiveness and safety of products, such studies should not commence before the studies set 369 
out to demonstrate clinical benefit within the original indication are well underway.36  370 
Drugs and devices approved on the basis of earlier-stage data (i.e., without active 371 
comparators, using only surrogate measures as study outcomes, in non-randomised studies)  372 
should be required by regulators in the post-marketing period to demonstrate their benefits in 373 
randomised trials with active and clinically-meaningful comparators that measure patient-centred 374 
clinical outcomes that belong to the set of core outcomes for the disease of interest. Although 375 
the regulatory agencies currently lack the statutory authority to require such studies outside of 376 
certain programs (e.g., accelerated approval pathway in the US), legislative change should be 377 
sought to enable such requirements. 378 
Requiring additional studies in the post-marketing period need not adversely affect 379 
investment in drug and device development. In 2008, the FDA issued guidance on the need for 380 
outcome trials to assess the cardiovascular safety of new diabetes drugs. Since the FDA’s 381 
guidance, the research and development landscape for diabetes has significantly improved, with 382 
several products demonstrating a positive effect on cardiovascular outcomes.83 Evidence to date 383 
suggests that FDA’s regulatory action has not negatively affected drug development.84 384 
 385 
3. Consider a range of active comparators: alternative drugs, devices, and non-drug treatments 386 
In therapeutic areas with an established standard of therapy, post-marketing studies 387 
should adopt active comparators. Post-marketing studies may need to keep pace, in a more 388 
adaptive fashion, with evolution in usual care. It is sometimes challenging to choose the most 389 
appropriate comparator. Network meta-analysis could help identify the best active comparator 390 
and address uncertainties in the available evidence base.85 Industry sponsors have an obligation 391 
to test the comparative benefits and harms of their new products against existing alternatives. 392 
However, given the importance of this research agenda and the evidence so far suggesting that 393 
industry has not always fulfilled this responsibility, independent organisations should play a 394 
greater role in designing and running post-marketing trials, ideally leveraging funding from 395 
industry (see recommendation 7).  396 
 Public and non-governmental funders such as the Patient-Centred Outcomes Research 397 
Institute in the US and the National Institute for Health Research in the UK should prioritise 398 
sponsoring research studies comparing different treatments (e.g., medical therapy vs. device; 399 
drug vs. exercise intervention), including alternative service packages, care pathways, and digital 400 
treatments.86 Informative studies may pit one treatment strategy against another (e.g., 401 
psychotherapy vs drug treatment; digital therapeutic options vs. traditional therapeutic options). 402 
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Yet, such ground-breaking comparative effectiveness studies are too rare, in part due to the 403 
difficulty in designing and conducting such studies. Identifying the appropriate types of 404 
outcomes, comparisons, and follow-up durations is difficult in trials that compare different 405 
treatment categories, and patients and public should be actively and routinely involved in this 406 
process.   407 
Until relatively recently, only about a tenth of comparative effectiveness studies 408 
published in high-impact general medical journals compared pharmacological and non-409 
pharmacological interventions.43 In a recent systematic review of almost 400 randomised trials, 410 
there were no direct head-to-head comparisons of antihypertensive drugs and structured exercise 411 
interventions in terms of their blood pressure-lowering effects.87 Similarly, in a previous meta-412 
epidemiological review, there was a paucity of randomised trials that directly compared the 413 
mortality benefits of drug and non-drug interventions in major chronic conditions.88 In the 414 
absence of such evidence, clinical practice guidelines typically focus on different categories of 415 
interventions in isolation and important public health questions are still unanswered.  416 
 417 
4. Use non-randomised study designs more selectively 418 
Non-randomised study designs have a clear role for the post-market evaluation of safety, 419 
especially for rare or uncommon adverse effects.89 However, their role in the evaluation of more 420 
common effects of either harm or clinical benefit is contested. For example, the evidence of 421 
harm associated with rofecoxib was only fully realised after an analysis of ongoing RCTs. When 422 
evaluating clinical benefit, we recommend limiting the use of non-randomised studies in the 423 
post-marketing period to settings when the evidence of benefit is very large.90 According to 424 
previous theoretical and simulation studies, very large effects are those when a treatment appears 425 
at least 5 or 10 times more effective than its comparator.90–92 Validity of non-randomised studies 426 
can be strengthened by mandatory centralised pre-registration of analytical protocols and public 427 
availability of collected datasets.72  428 
 Non-randomised studies could also be used to evaluate whether drugs and devices with 429 
an optimal evidence package can be extended to populations outside of those included in RCTs. 430 
In the non-randomised EXPRESS study,93 urgent treatment of transient ischaemic attack and 431 
minor stroke with aspirin, blood pressure-lowering medication, and statin resulted in a reduction 432 
in 90-day recurrent stroke risk of 80% (adjusted hazard ratio: 0.20, 95% CI: 0.08-0.49). Although 433 
the magnitude of this effect was substantially larger than that obtained from previous RCTs,94 434 
these findings triggered a re-analysis and time-course evaluation of individual participant data 435 
from RCTs of aspirin versus placebo. This re-analysis confirmed the dramatic treatment effect 436 
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observed in the non-randomised study, which was due to an acute benefit of aspirin on the 90-437 
day risk of  recurrent stroke that had not been detected in the previous analyses of RCTs.95 438 
Notably, EXPRESS was nested in a population-based incidence study of all transient ischaemic 439 
attack and stroke with near-complete ascertainment of all patients and outcomes before and after 440 
the change in treatment practice, thereby reducing the selection biases inherent in non-441 
randomised studies, as well as maximising external validity – the study included all patients in the 442 
underlying population with the condition.  443 
 444 
5.  Improve the efficiency of randomised trials 445 
While RCTs in the post-marketing period can adopt simpler “pragmatic” designs (as they 446 
do not need to comply with strict regulatory agency requirements), they may also require 447 
complex design features to capture diverse clinical outcomes that may develop over long time 448 
horizons. Therefore, designing studies that are useful in the post-marketing period cannot 449 
happen unless there are drastic improvements in the efficiency of RCTs. Costs for clinical trials 450 
are very high, especially in the US. The median cost of pivotal regulatory trials was estimated at 451 
$19 million for drugs that received FDA approval between 2015 and 2016.96 However, there is 452 
significant variation in reported estimates, with cost per recruited patient ranging from $41 to 453 
$6,990 in different studies.97  454 
 RCTs could benefit from innovative methodological designs (i.e. adaptive design trials, 455 
basket trials, registry trials, umbrella protocols), which have their own strengths and weaknesses 456 
(Panel 1). A key driver of clinical trial expenses is the complexity of patient enrolment, trial 457 
procedures and data analysis.98 To overcome these problems, a new framework is needed which 458 
reduces the amount of transactions needed to get the data from a patient into a database for 459 
analysis.  460 
For example, the registry-based RCT design leverages data sampling from high-quality 461 
registries to facilitate high participant inclusion rates at relatively low costs and, therefore, may 462 
offer a robust mechanism by which relevant clinical questions are answered in the post-463 
marketing period. In such trials, online registration identifies patients eligible for inclusion, 464 
random allocation occurs in the registry, and study set-up is part of clinical care, including the 465 
informed consent process.99 Ensuring seamless integration of such trials into routine clinical 466 
practice may require buy-in from care providers and substantial investment from governments. 467 
Another necessary precondition for registry-based trials is the existence of a high-quality registry 468 
covering the population to be studied, as the quality of the study data is bound by the quality of 469 
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the data in the registry.100 Registries (as those in the Nordic countries and in the UK) offer a 470 
potential source of relevant data.101,102  471 
 472 
6. Invest in data infrastructure for comparative effectiveness research 473 
Electronic health records, administrative data, and clinical registries currently exist in 474 
silos in health care systems. Efforts are underway to build collaborative data infrastructures by 475 
linking and leveraging information obtained from separate sources. In compliance with existing 476 
regulations to protect the confidentiality of personal data (such as the European General Data 477 
Protection Regulation), we recommend accelerating these efforts to facilitate comparative 478 
effectiveness research in the post-marketing period,103 particularly for facilitating pragmatic 479 
RCTs. There are already examples of integrated partnerships involving clinical researchers in 480 
academia and industry, patients and institutions, also for medical devices.104,105 In 2015, the 481 
Patient-Centered Outcomes Research Institute developed a network including patient-powered 482 
research networks and clinical data research networks and launched the randomised 483 
ADAPTABLE (Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-Term 484 
Effectiveness) trial, which is currently underway, comparing two different aspirin doses in high-485 
risk patients with a history of heart disease.106 ADAPTABLE reflects a pragmatic design by 486 
embedding the RCT within usual care, recruiting a diverse patient population with minimal 487 
eligibility criteria, promoting the continuation of usual care without standardised treatment 488 
protocols, and relying on electronic data collection with reduced need for costly primary data 489 
collection.107  490 
Another US-based initiative, the National Evaluation System for Health Technology 491 
(NEST) focuses on medical devices and coordinates the participation of institutions in a data 492 
network to develop data quality and methods standards.108 The first NEST studies involve 493 
multiple health systems answering key clinical and safety questions on a range of medical devices 494 
from cardiac and orthopaedic implants to catheters used for soft-tissue ablation, intervertebral 495 
body fusion devices, and craniomaxillofacial distractors.104 496 
However, progress has been slow, mainly for concerns about the quality and 497 
interoperability of underlying data in such systems, as they are not collected for research 498 
purposes, and ethical issues regarding data availability and data sharing in non-randomised 499 
settings. The future post-marketing research agenda could greatly benefit from the direct 500 
engagement of patients by consenting to sharing their electronic data from multiple sources 501 
through mobile health apps and electronic platforms, with researchers, regulators and other 502 
stakeholders. Concerns about data sharing may pose challenges to such patient-powered research 503 
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efforts in the post-marketing period.  504 
 505 
7.  Create a new set of incentives and reinforce accountability  506 
Pharmaceutical and device manufacturers should be held accountable for demonstrating 507 
and confirming the clinical benefit of their products in approved indications. Several guiding 508 
principles should be considered to reinforce such accountability. First, the level of payment for 509 
drugs and devices should correspond to their added benefit according to robust comparative 510 
effectiveness studies. Second, longer marketing protections should be considered for products 511 
that convincingly demonstrate their superiority to established standards of care.109 Third, public 512 
reporting of best research practices in the post-marketing period may incentivise companies to 513 
invest in comparative studies.110 Fourth, regulatory approval may be more formally linked to 514 
payer policies such as coverage with evidence development whereby the treatment is only 515 
available within the context of an ongoing post-marketing clinical trial.111 However, such 516 
strategies should be used very selectively and designed carefully so that they do not place undue 517 
administrative burden on public payers.  518 
In terms of penalty mechanisms, regulatory agencies should more actively consider 519 
license suspensions, indication restrictions, monetary fines, or even market withdrawal on a case 520 
by case basis. FDA and EMA already have the statutory authority to impose monetary penalties 521 
for not completing some required studies in a timely manner in expedited programs for drugs. 522 
However, regulators currently lack the administrative capacity and financial resources to exercise 523 
these powers.112 Therefore, regulators have yet to penalise pharmaceutical manufacturers for not 524 
generating post-marketing data with due diligence. In Europe, the proposal to implement a 525 
conditional marketing authorisation pathway for high-risk and implantable devices was rejected, 526 
severely restricting attempts at enforcing accountability. This should be the focus of future 527 
legislative change. Experience to date suggests that sizeable penalties may be effective to change 528 
industry behaviour. Some of the largest corporate fines for criminal offences (imposed by the US 529 
Department of Justice and not by regulators) have been for pharmaceutical companies for off-530 
label promotion of their products.113 Such financial penalties and the media coverage associated 531 
with them affected subsequent marketing practices and use.114,115  532 
 533 
Conclusions 534 
Comparative evidence on the benefits and harms of new and existing drugs and devices 535 
rarely emerges in the post-marketing period. There is an opportunity to coordinate research 536 
efforts between before and after approval. Policymakers and regulators can incentivise the 537 
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generation of comparative data in the post-marketing period by ensuring that post-marketing 538 
studies directly correspond to the limitations of pre-approval studies; designing post-marketing 539 
studies hierarchically (first to confirm clinical benefit and then to examine generalisability); 540 
limiting the use of non-randomised study designs when evaluating clinical benefit; improving the 541 
efficiency of randomised trials; investing in data infrastructure; and creating new incentive and 542 
penalty mechanisms.  543 
  544 
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Panel 1. Innovative (or non-conventional) study designs for randomised trials. This panel 571 
aims to outline key features of selected innovative trial designs. Adaptive trials use information 572 
generated during trial conduct to alter subsequent operations in a pre-specified way. In 2018 the 573 
FDA provided a draft guidance on “master protocols”, which refer to a master (or core) 574 
protocol, upon which multiple questions can be asked about the effectiveness of interventions 575 
for a particular disease or condition. Novel trial designs that use master protocols include basket, 576 
umbrella and adaptive platform trials. Both elements (master protocol and adaptive design 577 
features) add complexity, but with the intent of improving the efficiency of knowledge 578 
generation. Registry-based trials include a randomisation module in a large inclusive clinical 579 
registry with unselected consecutive enrolment, to combine the advantages of a prospective 580 
randomised trial with the strengths of a large-scale all-comers clinical registry. 581 
 582 
Adaptive trials  583 
Adaptive trials are designed to maximise flexibility, without compromising the validity and 584 
integrity of the trial. Modifications (“adaptations”) to aspects of the ongoing trial can be pre-585 
specified and prospectively planned, including adding or dropping treatment arms, changing 586 
dosages, sample size re-estimations and alterations. Adaptive trials aim to identify the patients 587 
who are most likely to benefit from a treatment: 588 
• When single or multiple different disease populations are studied 589 
• When single or multiple interventions are studied; adaptive trials can utilise multiple 590 
therapies  591 
o The sample size can vary significantly from very large to small depending on the 592 
study sub-design, interim sample size reassessments are also utilised   593 
• Use: Both exploratory and confirmatory clinical trials  594 
• Advantage: Reduces the use of resources, decreases the time of trial completion, limits the 595 
number of participants allocated to inferior interventions and improves the probability of 596 
success of the trial  597 
• Disadvantage: Subject to operational bias, due to the leakage of interim results and the 598 
potential to influence investigator behaviour  599 
 600 
Basket trials 601 
Basket trials are used to test the effect of a single drug, or a combination of drugs on single 602 
mutation (a single target) in multiple diseases (‘baskets’):  603 
• When multiple disease populations are being studied  604 
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o Including different histology types or different tumour types, often referred to as 605 
‘histology independent’ 606 
• When a single intervention is studied, which is targeted, matched or is biomarker specific   607 
o The sample size is relatively large but typically smaller than umbrella trial sample 608 
sizes and are generally single-arm trials  609 
• Use: Commonly discovery-based trials used in early stages of development  610 
• Advantage: An efficient way of identifying if a drug targeting a specific genetic mutation in 611 
one site of the body may be effective in treating that same genetic mutation found in 612 
tumour located in a different part of the body  613 
• Disadvantage: The use of the underlying assumption that molecular profiling is a sufficient 614 
replacement of histological tumour typing 615 
 616 
Platform trials (or adaptive platform trials)  617 
(Adaptive) platform trials are able to study multiple interventions in a disease or condition in a 618 
perpetual manner, with interventions entering and leaving the platform on the basis of a 619 
predefined decision algorithm.  620 
• When a single disease population is studied, usually limited to a single disease or single 621 
histology/tumour type   622 
o A broad cohort of participants are enrolled, and later stratified into different 623 
subtypes based on clinical or biomarker criteria 624 
• When multiple interventions are studied; they utilise multiple therapies in a perpetual trial 625 
design 626 
o Large sample sizes are often required as platform trials have the capacity to add 627 
and drop trial arms as futility or efficacy are demonstrated, often using a decision 628 
algorithm 629 
• Use: Can range from proof of concept studies through to confirmation of application 630 
trials  631 
• Advantage: Platform enables characterisation of the safety and efficacy of novel treatment 632 
combinations, potentially across diseases, mechanisms and sponsors, that would 633 
otherwise not be feasible in one trial  634 
• Disadvantage: Potential complexity of the trial implementation and planning, often 635 
requiring complex collaborations across sponsors and participating sites 636 
  637 
 638 
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Registry-based trials  639 
Registry trials are pragmatic trials that use registries as platforms for health records, data 640 
collections, randomisation and follow-up. The advancement of electronic data collection systems 641 
has led to the increasing number of developed registries used for research, policy, and 642 
administrative purposes. A clinical registry can be used for collection of baseline variables and to 643 
identify eligible patients for a study:  644 
• When single or multiple different disease populations are studied 645 
• When single or multiple interventions are studied 646 
o Typically use large sample sizes as large observational cohorts of patients.  647 
• Use: Often later on in drug development, and not suitable for trials that need 648 
comprehensive safety reporting or intense pharmacokinetic or pharmacodynamic 649 
profiling  650 
• Advantage: Low cost, enhanced generalisability of findings (real-world setting), rapid 651 
consecutive enrolment and follow-up  652 
• Disadvantage: Variable data quality, potentially poorly defined variables, limited facility to 653 
collect detailed safety reporting  654 
 655 
Umbrella trials  656 
Umbrella trials are designed to evaluate the impact of different drugs on different mutations in a 657 
single type of cancer: 658 
• When a single disease population is studied: trials are limited to a single disease or single 659 
histology/tumour type   660 
o Multiple biomarker matched subgroups of patients are used, patients are assigned 661 
to biomarker subgroups using a biomarker allocation algorithm 662 
• When multiple interventions are studied; umbrella trials utilise multiple therapies  663 
o Large sample sizes are often required, patients with multiple biomarkers can be 664 
included in more than one trial arm 665 
• Use: Can range from proof of concept studies to confirmation of application trials  666 
• Advantage: Capacity to draw meaningful conclusions specific to a tumour type  667 
• Disadvantage: Flexibility is limited, due to use of a single tumour type, particularly with 668 
rare diseases, where further subclassification may lead to poor accrual. 669 
  670 
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Table 1. Strategies aimed at incentivising pharmaceutical and device manufacturers to generate comparative data on drugs and high-risk and 694 
implantable devices in the post-marketing period, with a summary of the key recommendations and the target stakeholders. 695 
 696 
Overall strategies Key recommendations Target stakeholders  
(in alphabetical order) 
(1)   Ensuring post-
marketing studies 
address evidence 
gaps 
• Develop a customised plan to guide subsequent post-marketing research 
efforts  
• Ensure that future studies correspond directly to the limitations of the 
data available at the time of market entry 
• Health technology assessment 
organisations 
• Public payers 
• Regulatory agencies (FDA and EMA) 
(2)   Designing post-
marketing studies 
hierarchically 
• Products approved on the basis of studies without active comparators 
should be required to have active-comparators (or controlled trials 
compared with an known effective control)*. 
• Products approved on the basis of surrogate measures alone should be 
required to confirm their clinical benefit on patient-relevant outcomes. 
• Products approved on the basis of non-randomised study designs 
should be required to have randomised trials.  
• Once randomised trials with active-comparators and clinical outcomes 
are available, post-marketing research efforts should pivot to evaluating 
the applicability of evidence to broader patient populations over longer 
time horizons. 
• Device manufacturers 
• Pharmaceutical manufacturers 
• Regulatory agencies (FDA and EMA) 
• Government research funding bodies 
 
(3)   Considering active 
comparators beyond 
drugs and devices 
• Network meta-analyses should be used to choose appropriate active 
comparators. 
• Active comparators should include non-pharmacological interventions. 
• Device manufacturers 
• Government research funding bodies 
• Non-governmental research funders 
• Pharmaceutical manufacturers 
(4)   More selective use of 
non-randomised 
study designs  
• When evaluating clinical benefit, non-randomised studies should be used 
only when the evidence of benefit is overwhelmingly positive. 
• When randomised trials are available, non-randomised studies should be 
used to evaluate applicability to populations outside of those included in 
trials.  
• Device manufacturers 
• Government research funding bodies 
• Non-governmental research funders  
• Pharmaceutical manufacturers 
• Regulatory agencies (FDA and EMA) 
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(5)   Improving the 
efficiency of 
randomised trials 
• Randomised trials should adopt innovative design elements to improve 
efficiency of patient recruitment and data collection. 
• Device manufacturers 
• Government research funding bodies 
• Non-governmental research funders 
• Pharmaceutical manufacturers 
(6)   Investing in data 
infrastructure for 
comparative 
effectiveness research 
• Efforts aimed at establishing collaborative research networks and data 
systems should be accelerated.  
• Governments 
(7)   Creating a new set of 
incentives and 
reinforcing 
accountability 
• Payment for new drugs and devices should correspond to their added 
benefit over existing alternatives. 
• Penalties should be invoked for not generating comparative data in the 
post-marketing period.  
• Governments 
• Health technology assessment 
organisations 
• Public payers 
• Regulatory agencies (FDA and EMA) 
 697 
 698 
 699 
 700 
*  Active comparator trials may include head to head comparisons of a new product with a known effective treatment; the addition of the product to 701 
current effective treatment versus that same treatment used alone; and placebo-controlled trials of the new product when given in addition to best 702 
standard care. The essential requirement is that the new product (alone or in combination) is being compared with a known effective therapy.703 
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